Dell'Orso S - Search Results

1

Mutant p53: an oncogenic transcription factor.

Strano S, Dell'Orso S, Di Agostino S, Fontemaggi G, Sacchi A, Blandino G. Strano S, et al. Oncogene. 2007 Apr 2;26(15):2212-9. doi: 10.1038/sj.onc.1210296. Oncogene. 2007. PMID: 17401430 Review.

2

Mutant p53 proteins: between loss and gain of function.

Strano S, Dell'Orso S, Mongiovi AM, Monti O, Lapi E, Di Agostino S, Fontemaggi G, Blandino G. Strano S, et al. Head Neck. 2007 May;29(5):488-96. doi: 10.1002/hed.20531. Head Neck. 2007. PMID: 17123310 Review.

3

The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis.

Fontemaggi G, Dell'Orso S, Trisciuoglio D, Shay T, Melucci E, Fazi F, Terrenato I, Mottolese M, Muti P, Domany E, Del Bufalo D, Strano S, Blandino G. Fontemaggi G, et al. Nat Struct Mol Biol. 2009 Oct;16(10):1086-93. doi: 10.1038/nsmb.1669. Epub 2009 Sep 27. Nat Struct Mol Biol. 2009. PMID: 19783986

4

ChIP-on-chip analysis of in vivo mutant p53 binding to selected gene promoters.

Dell'Orso S, Fontemaggi G, Stambolsky P, Goeman F, Voellenkle C, Levrero M, Strano S, Rotter V, Oren M, Blandino G. Dell'Orso S, et al. OMICS. 2011 May;15(5):305-12. doi: 10.1089/omi.2010.0084. Epub 2011 Feb 19. OMICS. 2011. PMID: 21332394

5

The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs.

Di Agostino S, Cortese G, Monti O, Dell'Orso S, Sacchi A, Eisenstein M, Citro G, Strano S, Blandino G. Di Agostino S, et al. Cell Cycle. 2008 Nov 1;7(21):3440-7. doi: 10.4161/cc.7.21.6995. Epub 2008 Nov 16. Cell Cycle. 2008. PMID: 18948736

6

Id2 gene is a transcriptional target of the protein complex mutant p53/E2F1.

Fontemaggi G, Dell'Orso S, Muti P, Blandino G, Strano S. Fontemaggi G, et al. Cell Cycle. 2010 Jun 15;9(12):2464-6. doi: 10.4161/cc.9.12.11915. Epub 2010 Jun 15. Cell Cycle. 2010. PMID: 20519942 Free article. No abstract available.

7

ID4: a new player in the cancer arena.

Dell'Orso S, Ganci F, Strano S, Blandino G, Fontemaggi G. Dell'Orso S, et al. Oncotarget. 2010 May;1(1):48-58. doi: 10.18632/oncotarget.108. Oncotarget. 2010. PMID: 21293053 Free PMC article.

8

miR-155 harnesses Phf19 to potentiate cancer immunotherapy through epigenetic reprogramming of CD8⁺ T cell fate.

Ji Y, Fioravanti J, Zhu W, Wang H, Wu T, Hu J, Lacey NE, Gautam S, Le Gall JB, Yang X, Hocker JD, Escobar TM, He S, Dell'Orso S, Hawk NV, Kapoor V, Telford WG, Di Croce L, Muljo SA, Zhang Y, Sartorelli V, Gattinoni L. Ji Y, et al. Nat Commun. 2019 May 14;10(1):2157. doi: 10.1038/s41467-019-09882-8. Nat Commun. 2019. PMID: 31089138 Free PMC article.

9

The Histone Variant MacroH2A1.2 Is Necessary for the Activation of Muscle Enhancers and Recruitment of the Transcription Factor Pbx1.

Dell'Orso S, Wang AH, Shih HY, Saso K, Berghella L, Gutierrez-Cruz G, Ladurner AG, O'Shea JJ, Sartorelli V, Zare H. Dell'Orso S, et al. Cell Rep. 2016 Feb 9;14(5):1156-1168. doi: 10.1016/j.celrep.2015.12.103. Epub 2016 Jan 28. Cell Rep. 2016. PMID: 26832413 Free PMC article.

10

The Elongation Factor Spt6 Maintains ESC Pluripotency by Controlling Super-Enhancers and Counteracting Polycomb Proteins.

Wang AH, Juan AH, Ko KD, Tsai PF, Zare H, Dell'Orso S, Sartorelli V. Wang AH, et al. Mol Cell. 2017 Oct 19;68(2):398-413.e6. doi: 10.1016/j.molcel.2017.09.016. Epub 2017 Oct 12. Mol Cell. 2017. PMID: 29033324 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

59 results

Search Page

Filters